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uring recent years biomarkers have received
increasing attention in all medical specialties, but it is
particularly in the field of psychiatry that biomarkers are
expected to gain a more specific position. Up to now,
despite several decades of intensive research, the biol-
ogy of psychiatric disorders remains more or less elusive,
and is more challenging than in any other spectrum of
diseases in terms of diagnostic diversity, pathophysiol-
ogy, and response to treatment. 
The latter is particularly important since, despite the
availability of a set of therapeutic tools including phar-
macotherapy, psychotherapy, and biological therapies,
there are still unmet needs regarding onset of action,
stability of response, and further improvement of the
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Biomarkers have been receiving increasing attention, especially in the field of psychiatry. In contrast to the availabil-
ity of potent therapeutic tools including pharmacotherapy, psychotherapy, and biological therapies, unmet needs
remain in terms of onset of action, stability of response, and further improvement of the clinical course. Biomarkers
are objectively measured characteristics which serve as indicators of the causes of illnesses, their clinical course, and
modification by treatment. There exist a variety of markers: laboratory markers which comprise the determination of
genetic and epigenetic markers, neurotransmitters, hormones, cytokines, neuropeptides, enzymes, and others as sin-
gle measures; electrophysiological markers which usually comprise electroencephalography (EEG) measures, and in
particular sleep EEG and evoked potentials, magnetic encephalography, electrocardiogram, facial electromyogra-
phy, skin conductance, and others; brain imaging techniques such as cranial computed tomography, magnetic reso-
nance imaging, functional MRI, magnetic resonance spectroscopy, positron emission tomography, and single photon
emission computed tomography; and behavioral approaches such as cue exposure and challenge tests which can be
used to induce especially emotional processes in anxiety and depression. Examples for each of these domains are pro-
vided in this review. With a view to developing more individually tailored therapeutic strategies, the characterization
of patients and the courses of different types of treatment will become even more important in the future. .      
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PAGES_12_AG_1003_BA.qxd:DCNS#49  31/05/11  0:16  Page 225clinical course. Psychiatric disorders still show a wide
diagnostic variability, for example, the differential diag-
nosis of early uni- vs bipolar disorders, the differenti-
ation within the schizoaffective spectrum (between the
bipolar and schizophrenic pole) or the comorbidity of
anxiety spectrum disorders and depressive spectrum
disorders. Hence, for an apparently similar phenotype,
the relevant biomarkers may vary considerably, lead-
ing to a blurred relationship between distinct bio-
markers and psychopathologically defined nosological
entities. Biomarkers are regularly determined by tech-
nical, somewhat “objective” means using chemical or
physical measures.
1 In contrast, the clinical diagnosis of
any psychiatric disease and monitoring of the clinical
course either during the patient’s everyday life or dur-
ing clinical trials of therapeutic interventions is still car-
ried out by psychometric and somewhat “subjective”
means. Despite a considerable and immense set of psy-
chological measures, the rating within each test is done
by psychiatrists and psychologists, who of course are
trained, but still subject to their individual points of
view. This incurs an additional considerable risk of vari-
ation. 
Importantly, the stability of diagnoses varies over the
long-term course of psychiatric diseases.
2 Hence, even
variability between raters at the same time point can
occur, and during extended periods of observation dis-
tinct measures may vary considerably. This leads to the
problem of whether pathological findings represent a
“state” or “trait” phenomenon, whereby “state” may
represent either a stable condition apparent at the
onset of the disease or a biological “scar” as late
sequela of this disease. Currently some biomarkers are
regarded as state markers such as genetics and related
findings, in addition, several markers are putative trait
markers. Both state and trait markers carry distinct
information which provides the possibility of charac-
terizing treatment outcome better than mere subjective
measures. 
Definition
The term “biomarker” is not always appropriately
used, given the great diversity of methods and investi-
gational procedures to identify the origin or “state” of
psychiatric disorders. Moreover, for drug development
it also appears necessary to identify “trait” alterations;
this is of importance for identification of parameters
monitoring the intrinsic course of illness on one hand
and predicting the efficacy of treatment procedures on
this intrinsic course on the other hand. From this point
of view for biomarkers individual dynamic respon-
siveness to interventions is also interesting. Absolute
measures are helpful in identifying, eg, alterations in
comparison of patients vs controls. However, of further
interest is the way the individual response has to be
classified: within the physiological bandwidth of home-
ostasis or at the borders of individual regulatory
capacity. 
According to Frank and Hargreaves,
1 biomarkers are
characteristics which are objectively measured and
evaluated as an indicator of the intrinsic causes of ill-
nesses, the clinical course, and its modification by
treatment. In this context the authors point to the
differentiation of clinical end points of treatment
and surrogate end points: the former is for psychi-
atric approaches reflected by behavior and subjec-
tive feelings. For the latter the surrogate end point
substitutes a clinical end point, to predict clinically
wanted or unwanted effects. In addition, different
types of biomarkers can in general be classified as
shown in Table I 
3: 
Another aspect comprises the terms sensitivity and
specificity. Sensitivity and specificity are statistical
measures of the performance of binary classification
tests. Sensitivity measures the proportion of measures
or markers which correctly identify a condition, speci-
ficity measures the proportion of negative measures,
which resembles the concept of Type I and Type II
errors.
4 In the spectrum of biomarkers there is consid-
erable variability with regard to sensitivity and speci-
ficity. 
Up to now, and especially in the past decade, a multitude
of procedures have been developed, which may be listed
as follows (adapted from ref 5, but not an exhaustive list
of approaches -Table II):
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￿ Type 0 biomarkers are markers of the intrinsic cause of an illness 
and its longitudal course
￿ Type 1 markers identify the effects of an intervention by a 
specific drug action
￿ Type 2 markers are surrogate end points which predict the 
clinical course.
Table I. Types of biomarkers.
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chiatric diseases, at a very early stage the analysis of con-
centrations and the presence or absence of markers are
important approaches for characterizing, in addition to
the behavioral characteristics of efficacy, the global “phe-
nome” of the patient’s condition. 
Examples of biomarkers in depression, 
anxiety disorders, and schizophrenia
Genetics
Modern antidepressant drugs are, in terms of efficacy,
largely similar to drugs discovered several years ago. The
development of new treatments for depression is limited
by the availability of validated human biomarker mod-
els.
15 Family studies have revealed that the clinical
response to antidepressant treatment shows more simi-
larities within one family compared with controls, which
indicates that uptake, metabolism, transport of drugs, and
receptor binding is subjected to genetically controlled
enzymes, receptor expression, and others factors. 
Monoamine transporters, including the serotonin, norep-
inephrine, and dopamine transporters are important in
regulating neurotransmission by uptake of respective
transmitters released from nerve terminals. Regarding
serotonin transporter gene length polymorphisms, Caspi
and colleagues
16 concluded that in interaction with stress-
ful life events the genetic variation in the promoter region
plays a role in predisposition to major depression. In the
context of selective serotonin reuptake inhibitors in treat-
ment of depression and the well-established link between
stressful life events and depression, this finding offered a
convincing biological link. This result, however, could not
be confirmed by metanalyses of 14 studies
17 and a birth
cohort study in nearly 900 participants
18: neither a risk ele-
vation nor stable gene x environment interactions were
able to be proven. These findings question the suitability
of single-gene expression alterations for differentiation of
patients in clinical trials. Genome-wide association studies
point to multiple loci which in combination with additional
clinical characteristics may be better suited for predicting
treatment responses.
19 One of the largest recent cohort
studies for evaluation of treatment algorithms is the
Sequenced Treatment Alternative to Relieve Depression
(STAR*D) trial, which provided DNA from nearly 2000
patients with nonpsychotic depression. Variants in the
serotonin 2A receptor, the subunit of the glutamate-
kainate receptor (GRIK4) the potassium channel
(KCNK2) the chaperone FKBP5, a protein important for
HPA axis regulation, were associated with citalopram
treatment outcome.
20,21 For example, participants who were
homozygous for the A allele of the serotonin 2A receptor
had an 18% reduction in absolute risk of having no
response to treatment.
22Analyzing the BDNF ValMet66
polymorphism, no evidence of an association with treat-
ment outcome in STAR*D could be found.
23
There is also evidence for a complex inheritance with
multiple genes in the etiology of panic disorder. So far it
has not been possible to identify single major responsible
genes. Again, several genes of classical neurotransmitter
systems have been reported to be associated, eg, genes of
the serotonin transporter length polymorphisms, of the
monoamine oxidase A, catechol-O-methyltransferase,
adenosine receptor, and cholecystokinin B.
24After treat-
ing healthy volunteers with escitalopram, the induction of
panic-like anxiety by cholecystokinin tetrapeptide was sig-
nificantly more pronounced in the short/short genotype
subjects during escitalopram vs placebo pretreatment, and
no inhibitory effect of escitalopram upon panic-like symp-
toms elicited by choleystokinin tetrapeptide could be
demonstrated.
14 These findings support the notion that
gene x treatment effects are highly complex and subject
to a variety of influential factors. 
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￿ Laboratory markers which comprise the determination of genetic 
and epigenetic markers, transmitters, hormones, cytokines, 
neuropeptides, enzymes, and others as single measures;
this approach is also suited to reflecting the investigation of 
complex biological systems in its approximated entirety which is  
frequently described as a genome, proteome, and metabolome
6
￿ Electrophysiological markers which regularly comprise, eg, 
electroencephalography (EEG) measures
7 (and particularly sleep 
EEG and evoked potentials),
8 magnetic encephalography, 
electrocardiography, and in particular heart rate variability 
analyses,
9 facial electromyography analysis for emotion 
processing,
10 skin conductance, and others
￿ Brain imaging techniques like cranial computed tomography, 
magnetic resonance imaging (MRI), functional MRI (fMRI), 
magnetic resonance spectroscopy (MRS), positron emission 
tomography (PET) and single-photon emission computed 
tomography (SPECT)
11,12
￿ Behavioral approaches such as cue exposure and challenge tests 
which can be used to induce or monitor especially emotional 
processes in anxiety and depression.
13,14
Table II. Targets of biomarkers.
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amo-pituitary-adrenocortical (HPA) axis regulation in
depression and anxiety disorders: corticotropin-releas-
ing hormone (CRH) related peptides, gluco- and min-
eralocorticoids and their receptors play an important
role in behavioral, endocrine, and autonomic responses
to stress, which is thought to be important in depression
and anxiety. The chaperone FKBP5, a protein involved
in HPA axis regulation, has been shown to mediate
interaction effects with other polymorphisms.
21 Selective
antagonists have been used experimentally to elucidate
the role of CRH-related peptides, but up to now the
development of specific drugs has been challenging
25,26
and tests of these compounds in genetically well-char-
acterized patient samples remain to be tested. 
Schizophrenia is also the result of genetic alterations.
However, genetic research has been impaired by the
lack of disease-specific biomarkers. Despite an estimated
70% to 80% heritability of schizophrenia, nongenetic
factors considerably modify the incidence and course of
this disease, which complicates the identification of sus-
ceptibility genes.
27 Genes such as DISC1 include existing
targets for drug development in schizophrenia and
depression,
28 but are not specific for schizophrenia. 
The wide interindividual variability in clinical efficacy and
tolerability of antipsychotic medications led investigators
to relate not only efficacy of antipsychotic medications
but side-effect profiles to pharmacogenetic factors.
29
However, up to now, only a few genome-wide association
studies, eg, the CATIE trial with atypical antipsychotic
treatment, are available which might lead to novel genes
important for the efficacy of antipsychotics.
30
Pharmacogenetics
In the context of pharmacogenetics, there was a goal of
establishing individualized pharmacotherapy.
31 Genes
encoding for enzymes involved in phase 1 metabolism
are mainly cytochrome P450 (CYP) enzymes, which are
known to contain a large variety of functional polymor-
phisms that significantly alter their metabolic activity.
Common CYP polymorphisms can be distinguished by
their effects upon metabolic rate, identifying the enzyme
as slow (poor metabolizers), rapid (extensive metaboliz-
ers), or ultrarapid (ultrarapid metabolizers).
32 In partic-
ular, CYP2D6, a hepatic enzyme involved in the metab-
olism and elimination of antidepressants and
antipsychotics, has been thoroughly investigated and
associated with loss of efficacy or the potential to develop
toxic reactions. Individuals presenting CYP2D6 PM vari-
ants are more likely to develop extrapyramidal side
effects and weight gain. Kirchheiner and Rodriguez-
Antona
33 showed that CYP2D6 and CYP2C19 metabolic
rates may have an important influence upon the required
doses of antidepressants and antipsychotics. This is an
example for the clinical use of pharmacogenetics, espe-
cially when combined with clinical informations. 
The geographical distribution of CYP2D6 variants is het-
erogenous, supporting the notion that metabolic poly-
morphisms account for a significant part of variability in
response to medications. Functional polymorphisms have
been observed also in genes coding for CYP1A2, CYP2C9,
CYP2C19, and CYP3A4 enzymes. Whereas CYP2C19
may be clinically relevant for the metabolism of antide-
pressants, CYP1A2 and CYP3A4 are major metabolic
pathways of most commonly used antipsychotics, eg, olan-
zapine, risperidone, aripiprazole, and clozapine. Slow
CYP1A2 variants have been associated with increased risk
of drug-induced side effects. Since smoking can induce
CYP1A2 activity, this example of a gene x environment
interaction may have clinical significance: individuals with
CYP1A2 rapid phenotypes who smoke are known to
experience an impaired response to treatment with cloza-
pine, a CYP1A2 substrate. Few reports have investigated
CYP3A4, CYP2C9, and CYP2C19 functional variants and
their influence on clinical outcome, with only some refer-
ence to the influence of CYP2C19 variants on therapeutic
doses of antidepressants.
34Whereas it has been postulated
that clinical trials should include measurements of blood
concentrations during drug development to generate more
valid data about the relationship between drug concen-
trations and clinical outcomes under controlled condi-
tions,
35 up to now no studies have reported on the prospec-
tive use of CYP genotyping in clinical practice.
36
Regarding the pharmacodynamics of the respective types
of drugs, genetic polymorphisms in serotonin, noradrena-
line, and dopamine receptors have been extensively inves-
tigated. Again, no single but multiple genes play a role in
complex phenotypes, including the clinical response to
medication. Thus, a multiple candidate gene approach has
recently been adopted in pharmacogenetics. The new field
of pharmacogenomics using DNA microarray analysis,
which focuses on the genetic determinants of drug
response at the level of the entire human genome, is
important for development and prescription of, eg, safer
and more effective individually tailored antipsychotics.
37
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Studies with profiling experiments on brain physiology
have to rely largely on postmortem analyses, which carry
the risk of artefacts. Approaches to parallel alterations
of the transcriptome, proteome, and metabolome in
brain to findings in blood and cerebrospinal fluid (CSF)
are possibly capable of providing experimental evidence
for molecular findings in psychiatric disorders which
help to identify also treatment responses.
6 Using pro-
teomics to investigate distinct protein patterns is promis-
ing to improve the biology of psychiatric disorders and
to identify biomarkers.
38 Also, knowledge of biochemi-
cal pathways can provide disease marker information
required for drug development and improved patient
treatment. Therefore, approaches to identifying path-
ways that affect depression-, anxiety- and schizophrenia-
like phenotypes could be important.
39 Due to the close
proximity of CSF to the brain, pathological brain
processes are more likely to be reflected in CSF than in
blood or saliva,
40 and especially new tools like capillary
electrophoresis-mass spectrometry in proteome analy-
sis
41 could also reveal new proteins in CSF that are suited
as biomarkers for treatment responses. 
Neuroendocrinology and hypothalamic-pituitary-
adrenal axis alterations
Particularly in depression, but also in anxiety disorders,
frequently alterations of the hypothalamic-pituitary-
adrenal (HPA) axis are observed. Besides steroids,
numerous other factors regulate HPA axis responsive-
ness: at the hypothalamic level corticotrophin-releasing
hormone (CRH) and receptors such as the CRH1- and
CRH2-receptor,
42 modulators such as agonistic vaso-
pressin
43 and antagonistic atriopeptins 
44,45 are involved
in the central regulation of HPA activity. At the molec-
ular level, glucocorticoid receptor polymorphisms may
be associated either with hypofunction or hyperfunction
which could contribute to these findings.
46 Other factors
are the influences of steroids like estrogen and proges-
terone. However, immune molecules, such as inter-
leukins and cytokines, also activate the HPA axis and
alter brain function, including cognition and mood.
47
Regarding treatment outcome, pivotal studies have been
conducted in the past, applying the dexamethasone-
induced suppression of HPA activity, the CRH stimula-
tion test of HPA activity, and the combined dexametha-
sone-CRH test to predict treatment reponse.
48 In an
investigation by Schüle et al
49 the attenuation of HPA
axis activity after 1 week of antidepressant pharma-
cotherapy was significantly associated with subsequent
improvement of depressive symptoms. Also, other single
tests revealed a predictive potency of the dexametha-
sone-CRH test.
50 These findings are in line with studies
reported by Ising et al,
51 who found normalized HPA
activity in a subsequent dexamethasone-CRH test 2 or
3 weeks after the first test at beginning of treatment with
an association of psychopathological improvement after
5 weeks. Interestingly, the effects of CRH-1 receptor
antagonists
25 and glucocorticoid receptor antagonists
52
could not be predicted by defined alterations of HPA
activity before treatment. In line with this, HPA axis
activity also did not predict the efficacy of cortisol syn-
thesis inhibitors in treatment of depression.
53
Sleep electroencephalography
Sleep electroencephalogram (EEG) analysis provides
markers of depression
54,55 and for antidepressant ther-
apy.
8 For a long time it has been known that EEG activ-
ity is altered by drugs. Quantitative EEG analysis helps
to delineate effects of antidepressants on brain activity.
Elevated rapid eye movement (REM) density, which is
a measure of frequency of REM, characterizes an
endophenotype in family studies of depression. For
example, for paroxetine REM density after 1 week of
treatment was a predictor of treatment response.
56
Most antidepressants suppress REM sleep in depressed
patients and normal controls, but REM suppression
appears not to be crucial for antidepressant effects. Sleep
EEG variables like REM latency and other variables
were shown to predict the response to treatment with an
antidepressant or the course of the depressive disorder.
Some of these predictive sleep EEG markers of the
long-term course of depression appear to be closely
related to hypothalamo-pituitary-adrenocortical system
activity.
8,54
Challenge studies
To experimentally induce fear, or panic anxiety, several
approaches with a large variety of agents have been con-
ducted for further elaboration of the physiological basis
of pathologic anxiety. Targets are the identification of
more effective anxiolytic compounds avoiding addictive
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variety of challenge paradigms were investigated to
establish the proof of concept in healthy volunteers.
Different types of models for patients and healthy vol-
unteers are available (Table III). 
However, these challenge paradigms fulfil the require-
ments of test-retest consistence and standardized
responsiveness to reference drugs only in part. Most of
them have been developed for the purpose of patho-
physiological studies,
58 using rating instruments validated
for clinical practice. Adapting these models to the
requirements of pharmaceutical trials involves possibly
a wider use of other biomarkers, and better characteri-
zation has to be carried out.
59
Whether human models can significantly enhance and
accelerate phase I studies remains elusive. For example,
experimental panic induction with cholecystokinin
tetrapeptide (CCK4) is considered a suitable model to
investigate the pathophysiology of panic attacks and a
variety of studies in patients and healthy volunteers have
been conducted. Some clinical trials have proven the
validity of CCK4 studies in selective serotonin reuptake
inhibitors,
60 benzodiazepine trials
61 and experimental
studies with neuropeptides and neurosteroids.
44,62 In con-
trast, CCK4 antagonist studies
63,64 have shown equivocal
effects in patients with panic disorder. Moreover, studies
in healthy men showed stimulatory effects of escitalo-
pram upon panic symptoms elicited by choleystokinin
tetrapeptide. These findings question the potential use-
fulness of this panic model for proof-of-concept studies.
14
Imaging
Brain imaging represents a tool to characterize state and
trait markers, also in disorders with an episodic course
such as schizophrenia and bipolar disorder. An inte-
grated approach to support diagnostic processes may
lead to a more accurate classification of depression.
11
Results of functional magnetic resonance imaging
(fMRI) indicate that both gray and white matter have
diagnostic and prognostic potential in major depression
and may provide an initial step towards the use of mark-
ers to predict efficacy of pharmacologic treatment.
65
Besides structural analyses, positron emission tomogra-
phy (PET) and single-photon emission computed
tomography (SPECT) are used to identify alterations of
neurotransmitters and their respective receptors in spe-
cific regions of the brains. Magnetic resonance spec-
troscopy (MRS) literature supports the presence of
brain metabolic alterations in relation to individual
mood state. An analysis of 31P-MRS studies regarding
brain energetic status and phospholipid metabolism pro-
vided support for state-specific alterations in bipolar dis-
order.
66 More generally, evidence for an abnormal brain
energy metabolism in mood disorders was found.
Metabolic aberrations may be intrinsic since, for exam-
ple, brain intracellular pH determined by 31P-MRS is
decreased in medication-free bipolar patients in manic,
depressed, and euthymic mood states.
12
Anxiety, and in particular panic disorder, has been
extensively investigated to link episodic pathological
Clinical research
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Panicogen Heart rate stimulation Dyspnea Respiratory stimulation HPA stimulation NE stimulation
Cognitive + + + - -
Lactate + + + - -
Bicarbonate - + + - -
CO2 ?+ + - -
Isoproterenol + + + ? ?
Caffeine + - + + -
Cholecystokinin-4 + + (+) + -
Pentagastrin + + (+) + ?
Yohimbine + - - + +
mCCP + - - + -
Fenfluramine + - - + -
β-Carboline + - - + +
Flumazenil ? - - - ?
Table III. Panic anxiety-inducing agents.
Adapted from ref 57: Nutt D, Lawson C. Panic attacks: a neurochemical overview of models and mechanisms. Br J Psychiatry. 1992;160:165-178. Copyright
© Royal College of Psychiatrists 1992
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hypothesized that respiratory dysregulation persists as a
trait finding, also in the asymptomatic state.
67 Patients
with panic disorder are susceptible to panic attacks pre-
cipitated by challenges like sodium lactate infusion, car-
bon dioxide inhalation, and hyperventilation (Table III).
Intravenous infusion of 0. 5 mol/L sodium lactate with
70 mL/kg body weight produces marked physiologic and
psychologic symptoms in panic patients but less fre-
quently in healthy controls.
58 Also in 1-h MRS studies
lactate infusion was used as a physiological challenge to
investigate brain metabolism. When the distribution of
lactate increases was assessed, abnormal brain lactate
increases were estimated as tissue-based due to brain
metabolic mechanisms. However, persistent brain lactate
rises in panic patients during treatment with, eg, fluoxe-
tine or gabapentin, indicate that brain lactate increases
are possibly independent of metabolic challenges, which
questions their suitability as markers.
66
Only a few fMRI studies have investigated the brain
activation patterns following CCK4 administration.
CCK4-induced anxiety was accompanied by strong and
robust activation in various areas. Analysis for placebo
and anticipatory anxiety generated no significant differ-
ences, and overall functional responses did not differ
between panickers and nonpanickers.
68 Up to now, no
fMRI studies have been conducted to predict treatment
response. 
In patients with schizophrenia especially, studies of spe-
cific receptors, such as the dopamine D2 receptor, before
and after administration of an antipsychotic, provide a
means to determine receptor occupation. PET findings
of high D2-receptor occupation in the striatum of
responders to different antipsychotics provided clinical
support for the dopamine hypothesis of antipsychotic
drug action. Patients with extrapyramidal syndromes
(EPS) show a higher occupancy—over 80%—than
patients with no EPS. The PET-defined interval for an
optimal antipsychotic drug treatment has been used in
dose recommendations for typical and atypical antipsy-
chotics. Interestingly, currently available PET ligands are
not selective for the five dopamine receptor subtypes.
69
However, up to now PET can be used to predict and
monitor extrapyramidal side effects of antipsychotic
treatment rather than therapeutic efficacy.
70
Summary
In this overview some biomarkers for future develop-
ment of psychopharmaceutical drugs have been exem-
plified for antidepressants, anxiolytics, and antipsychotics.
Due to the trend to develop more individually tailored
therapeutic strategies, the characterization of patients
and the course of treatment by different aspects will
become more important in the future. A better descrip-
tion of state and trait characteristics should enable us to
focus on a more specific individual “phenome” that is to
be treated. In applying biomarkers to therapeutic drug
development, additional aspects have to be taken into
account: the increasing frequency of psychiatric diagnoses
and especially of depression and anxiety and a trend to
denosologization during the past decades regarding
“depressive syndromes” and ”anxiety spectrum disor-
ders.” To predict or monitor treatment responses more
precisely, biomarkers will need to characterize the
patient’s condition in an integrated manner.  ❏
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Biomarcadores en el desarrollo de fármacos
psicotrópicos
Los biomarcadores han estado recibiendo creciente
atención, especialmente en psiquiatría. En contraste
con la disponibilidad de potentes herramientas
terapéuticas incluidas la farmacoterapia, la psico-
terapia y las terapias biológicas, aun hay necesida-
des insatisfechas en términos del comienzo de la
acción, la estabilidad de la respuesta y una mayor
mejoría del curso clínico. Los biomarcadores son
características mensurables objetivamente que sir-
ven como indicadores de las causas de la enferme-
dad, su curso clínico y la modificación por el trata-
miento. Existe una variedad de biomarcadores:
marcadores de laboratorio que incluyen la deter-
minación de marcadores genéticos y epigenéticos,
neurotransmisores, hormonas, citoquinas, neuro-
péptidos, enzimas, y otras mediciones aisladas; mar-
cadores electrofisiológicos que habitualmente inclu-
yen mediciones electroencefalográficas (EEG), y en
especial EEG del sueño y potenciales evocados,
encefalografía magnética, electrocardiograma,
electromiografía facial, conductancia de la piel y
otros; técnicas de imágenes como la tomografía
computada craneal, imágenes de resonancia mag-
nética, resonancia magnética funcional, espectros-
copia por resonancia magnética, tomografía por
emisión de positrones y tomografía computada por
emisión de fotón único, y aproximaciones conduc-
tuales como la exposición a señales y las pruebas de
desafío, las que pueden ser empleadas especial-
mente para inducir procesos emocionales en la
ansiedad y la depresión. En esta revisión se entre-
gan ejemplos de cada una de estas áreas. Con una
perspectiva de desarrollar estrategias terapéuticas
más a la medida de cada individuo, la  caracteriza-
ción de pacientes y los cursos de diferentes trata-
mientos llegarán a ser aun más importantes a
futuro. 
Les biomarqueurs dans le développement
des psychotropes
Une attention croissante est portée sur les biomar-
queurs, en particulier dans le domaine de la psy-
chiatrie. Alors que des outils thérapeutiques puis-
sants comme la pharmacothérapie, la psychothérapie
et les traitements biologiques sont disponibles, des
besoins non satisfaits persistent en termes de mise en
œuvre de la stratégie, de stabilité de la réponse et
d’amélioration ultérieure de l’évolution clinique. Les
biomarqueurs sont des caractéristiques mesurées
objectivement, servant d’indicateurs des causes des
pathologies, de leur évolution clinique et des chan-
gements dus au traitement. Il existe un grand
nombre de marqueurs : les marqueurs de laboratoire
qui comprennent la détermination des marqueurs
génétiques et épigénétiques, les neurotransmetteurs,
les hormones, les cytokines, les neuropeptides, les
enzymes et d’autres, comme mesures simples ; les
marqueurs électrophysiologiques habituellement
représentés par l’électroencéphalographie (EEG) et
en particulier l’EEG du sommeil et les potentiels évo-
qués, l’encéphalographie magnétique, l’électrocar-
diogramme, l’électromyographie faciale, la conduc-
tance cutanée et d’autres ; les techniques d’imagerie
cérébrale comme le scanner cérébral,  l’imagerie par
résonance magnétique, l’IRM fonctionnelle, la spec-
troscopie par résonance magnétique, la tomographie
par émission de positons et la tomographie par émis-
sion monophotonique (SPECT) ; et les approches
comportementales comme l’exposition à un signal et
les tests d’épreuve utilisés pour provoquer des pro-
cessus émotionnels  spécifiques dans l’anxiété et la
dépression. Cet article donne des exemples dans cha-
cun de ces domaines. La caractérisation des patients
et l’évolution des différents types de traitement
deviendront encore plus importants dans le futur,
avec l’espoir de développer des stratégies thérapeu-
tiques plus personnalisées. 
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